TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/Day When Added to Ongoing Therapy With a Statin Versus Statin Therapy Alone, in Patients With Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level
Brief Summary: The purpose of this 6-week study is to compare the reduction in specific levels of cholesterol in patients with high cholesterol.


Options:
A: Arm Label: EZ/Simva; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (plus simvastatin) | Arm Label: Placebo/Simva; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (plus simvastatin) | Intervention Type: DRUG; Name: ezetimibe (plus simvastatin); Assigned to Arm(s): EZ/Simva | Intervention Type: DRUG; Name: placebo (plus simvastatin); Assigned to Arm(s): Placebo/Simva
B: Arm Label: Extended release niacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: extended release niacin, Drug: ezetimibe | Arm Label: Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: ezetimibe | Intervention Type: DRUG; Name: extended release niacin; Assigned to Arm(s): Extended release niacin | Intervention Type: DRUG; Name: ezetimibe; Assigned to Arm(s): Extended release niacin, Ezetimibe
C: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Placebo QM; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Ezetimibe (Q2W); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Biological: Placebo to Evolocumab | Arm Label: Ezetimibe (QM); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Biological: Placebo to Evolocumab | Arm Label: Evolocumab Q2W; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Evolocumab QM; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Other: Placebo to Ezetimibe | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab Q2W, Evolocumab QM | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe (Q2W), Ezetimibe (QM) | Intervention Type: BIOLOGICAL; Name: Placebo to Evolocumab; Assigned to Arm(s): Ezetimibe (Q2W), Ezetimibe (QM), Placebo Q2W, Placebo QM | Intervention Type: OTHER; Name: Placebo to Ezetimibe; Assigned to Arm(s): Evolocumab Q2W, Evolocumab QM, Placebo Q2W, Placebo QM
D: Intervention Type: DRUG; Name: MK0653, ezetimibe; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: statins; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Ezetimibe + Simvastatin on Clinical Outcomes in Patients With Aortic Stenosis
Brief Summary: The purpose of this study is to evaluate whether treatment with an investigational drug as compared to placebo will reduce the risk of major cardiovascular events in patients with aortic stenosis.


Options:
A: Arm Label: EZ/Simva 10/40 mg; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (+) simvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): EZ/Simva 10/40 mg | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard therapy | Arm Label: fluvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluvastatin | Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): fluvastatin | Intervention Type: DRUG; Name: standard therapy; Assigned to Arm(s): standard therapy
D: Arm Label: ABT-335 plus rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: ABT-335 plus rosuvastatin | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: ABT-335 plus rosuvastatin; Assigned to Arm(s): ABT-335 plus rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis
Brief Summary: The purpose of this study is to compare the gastrointestinal tolerability of an investigational drug to an approved drug in the treatment of osteoarthritis during one year treatment period.


Options:
A: Intervention Type: DRUG; Name: MK0663, etoricoxib; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Diclofenac sodium; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: MK0663, etoricoxib; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Diclofenac sodium; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: MK0663, etoricoxib; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Diclofenac sodium; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Celecoxib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac + Omeprazole | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Diclofenac + Omeprazole; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis
Brief Summary: The purpose of this study is to evaluate the long-term safety of an investigational drug versus an approved drug for the relief of pain in patients with rheumatoid arthritis.


Options:
A: Intervention Type: DRUG; Name: MK0663, etoricoxib; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Diclofenac sodium; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: MK0663, etoricoxib; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Diclofenac sodium; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: MK0663, etoricoxib; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Diclofenac sodium; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Celecoxib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac + Omeprazole | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Diclofenac + Omeprazole; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Patients With Acute Asthma
Brief Summary: The purpose of this study is to evaluate improved results of treatment for patients entering an emergency department with asthma attacks when given an investigational IV administration of an approved drug (MK-0476, montelukast sodium) in addition to approved standard treatment.


Options:
A: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
B: Intervention Type: DEVICE; Name: Integrated Care Pathway; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: rhDNAse (pulmozyme); Assigned to Arm(s): N/A
D: Arm Label: Montelukast 7 mg; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): Montelukast 7 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Patients With Acute Asthma
Brief Summary: The purpose of this study is to evaluate improved results of treatment for patients entering an emergency department with asthma attacks when given an investigational IV administration of an approved drug (MK-0476, montelukast sodium) in addition to approved standard treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Montelukast plus prednisolone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Intervention Type: DRUG; Name: Montelukast plus prednisolone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): 2
B: Arm Label: Montelukast 7 mg; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): Montelukast 7 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Reduce Cardiovascular Events With Aranesp® Therapy
Brief Summary: The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage renal disease or death, in subjects with chronic kidney disease and type 2 diabetes mellitus.

Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD


Options:
A: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
B: Arm Label: Benson relaxation combined with music therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Benson relaxation combined with music therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Benson relaxation combined with music therapy; Assigned to Arm(s): Benson relaxation combined with music therapy
C: Arm Label: Vadadustat; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
D: Arm Label: tMBSR; Type: EXPERIMENTAL; Interventions: Behavioral: tMBSR | Arm Label: Support Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support group | Intervention Type: BEHAVIORAL; Name: tMBSR; Assigned to Arm(s): tMBSR | Intervention Type: BEHAVIORAL; Name: Support group; Assigned to Arm(s): Support Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Reduce Cardiovascular Events With Aranesp® Therapy
Brief Summary: The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage renal disease or death, in subjects with chronic kidney disease and type 2 diabetes mellitus.

Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD


Options:
A: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
B: Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): N/A
C: Arm Label: EPO rise; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietin administration | Arm Label: EPO stable; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietin administration | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythropoietin administration; Assigned to Arm(s): EPO rise, EPO stable
D: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Reduce Cardiovascular Events With Aranesp® Therapy
Brief Summary: The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage renal disease or death, in subjects with chronic kidney disease and type 2 diabetes mellitus.

Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin | Intervention Type: DRUG; Name: epoetin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
C: Arm Label: CKD-11101(Darbepoetin alfa); Type: EXPERIMENTAL; Interventions: Biological: CKD-11101(Darbepoetin alfa) | Arm Label: NESP(Darbepoetin alfa); Type: ACTIVE_COMPARATOR; Interventions: Biological: NESP(Darbepoetin alfa) | Intervention Type: BIOLOGICAL; Name: CKD-11101(Darbepoetin alfa); Assigned to Arm(s): CKD-11101(Darbepoetin alfa) | Intervention Type: BIOLOGICAL; Name: NESP(Darbepoetin alfa); Assigned to Arm(s): NESP(Darbepoetin alfa)
D: Arm Label: Erythropoiesis Stimulating Agents; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin Alfa, Drug: Epoetin Alfa, Drug: Epoetin Beta, Drug: methoxy polyethylene glycol-epoetin beta | Arm Label: Methoxy Polyethylene Glycol-Epoetin Beta; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa, Drug: Epoetin Alfa, Drug: methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta | Intervention Type: DRUG; Name: Epoetin Beta; Assigned to Arm(s): Erythropoiesis Stimulating Agents | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Reduce Cardiovascular Events With Aranesp® Therapy
Brief Summary: The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage renal disease or death, in subjects with chronic kidney disease and type 2 diabetes mellitus.

Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD


Options:
A: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA
B: Arm Label: Correction Phase: CERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera] | Arm Label: Correction Phase: Epoetin Beta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]; Assigned to Arm(s): Correction Phase: CERA | Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): Correction Phase: Epoetin Beta
C: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial to Reduce Cardiovascular Events With Aranesp® Therapy
Brief Summary: The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage renal disease or death, in subjects with chronic kidney disease and type 2 diabetes mellitus.

Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): 1
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
C: Arm Label: Peginesatide 0.025 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Peginesatide 0.04 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.025 mg/kg | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.04 mg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa
D: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of Daptomycin Compared to Conventional Therapy In the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to Staph Aureus
Brief Summary: The purpose of this study is to compare the safety and efficacy of daptomycin, an antibiotic, to standard therapy in subjects who have infective endocarditis or bacteremia due to Staphylococcus aureus (S. aureus).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fosfomycin and imipenem | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: DRUG; Name: Fosfomycin and imipenem; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): 2
B: Arm Label: Guideline treatment with parenteral antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guideline treatment with parenteral antibiotics | Arm Label: Oral treatment with antibiotics; Type: EXPERIMENTAL; Interventions: Drug: Oral treatment with antibiotics for endocarditis | Intervention Type: DRUG; Name: Oral treatment with antibiotics for endocarditis; Assigned to Arm(s): Oral treatment with antibiotics | Intervention Type: DRUG; Name: Guideline treatment with parenteral antibiotics; Assigned to Arm(s): Guideline treatment with parenteral antibiotics
C: Intervention Type: DRUG; Name: daptomycin; Assigned to Arm(s): N/A
D: Arm Label: TAVI cohort; Type: N/A; Interventions: Procedure: Aortic valve replacement | Arm Label: SAVR cohort; Type: N/A; Interventions: Procedure: Aortic valve replacement | Intervention Type: PROCEDURE; Name: Aortic valve replacement; Assigned to Arm(s): SAVR cohort, TAVI cohort

Answer: C